Trastuzumab Deruxtecan + Cetuximab for Colorectal Cancer

This trial tests a new treatment combination for individuals with colorectal cancer that has spread or cannot be surgically removed. The researchers aim to determine if trastuzumab deruxtecan (a targeted therapy) combined with cetuximab can effectively treat cancers with low levels of the HER2 protein, particularly if the cancer has worsened after standard treatments. The trial begins with a small group to assess safety, then expands to evaluate the treatment's effectiveness. This trial may suit those whose colorectal cancer has progressed despite previous treatments and who have tumors with specific genetic markers. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of participants.

Research has shown that trastuzumab deruxtecan (T-DXd) is generally well-tolerated by patients. In past studies involving patients with metastatic colorectal cancer, unwanted side effects occurred less frequently. However, serious risks such as interstitial lung disease and pneumonitis were fatal in about 0.9% of cases. Despite these risks, many patients responded positively to the treatment.

Researchers are excited about Fam-Trastuzumab Deruxtecan-Nxki for colorectal cancer because it employs a novel mechanism by delivering a potent anti-cancer drug directly into cancer cells, targeting HER2, a protein that can promote the growth of cancer cells. Unlike standard treatments that might involve chemotherapy or targeted therapies like EGFR inhibitors, this innovative drug conjugate combines targeted therapy with chemotherapy, potentially increasing effectiveness and reducing harm to healthy cells. The combination with Cetuximab further enhances the anti-cancer activity by targeting another pathway, which might improve outcomes for patients who have limited options with existing treatments.

Research has shown that the drug fam-trastuzumab deruxtecan-nxki, also known as Enhertu, delivers promising results in treating cancers linked to HER2 proteins. For instance, patients with HER2-low metastatic breast cancer experienced significant improvements in the stability of their cancer. In non-small cell lung cancer, this drug proves effective, particularly when cancer cells exhibit certain HER2 characteristics. These findings suggest that fam-trastuzumab deruxtecan-nxki effectively targets and attacks cancer cells with HER2 proteins. While specific data for colorectal cancer remains under study, this trial will evaluate the combination of fam-trastuzumab deruxtecan-nxki and cetuximab. The drug's success in similar HER2-related cancers supports its potential in this area.⁶⁷⁸⁹¹⁰